Arthneeti
All Q3 FY25 results →
JP

Jagsonpal Pharmaceuticals Ltd

Q3 FY25Pharmaceuticals & Biotechnology

Jagsonpal Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins

Q3 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹237
Market cap₹1.5K Cr
P/E31.8
Updated23 Aug 2026
Read4 min read

The short version

Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25 on a stable basis. Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25.

From Jagsonpal Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25 on a stable basis.
  • Growth drivers include approximately one-third volume growth, one-third price increases (3-5%), and one-third new product launches.
  • Recent product launches like FeProtein and LycoRed M are gaining traction, crossing INR 20 lakhs monthly sales.
  • The company expects continued organic growth in the base business, with an 8% organic growth rate YTD.
  • New product introductions are planned at 8-10 products annually, about two per division across four divisions.
  • No major changes in product mix expected organically; portfolio shifts will occur mainly through inorganic acquisitions.

2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No specific mention of current or future capital expenditure (capex) or strategic investments in manufacturing or infrastructure was highlighted.
  • The company emphasized a disciplined approach to cash utilization, prioritizing:
  • Inorganic growth opportunities such as acquisitions that fit strategic and pricing criteria.
  • No expansion in MR (Medical Representative) strength planned; focus is on productivity.
  • Cash balance expected to reach around INR 150 crores by year-end, generated mostly from operations and divestment of the Faridabad facility.

2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention the current or expected order book or pending orders for Jagsonpal Pharmaceuticals Limited. However, some relevant insights related to business stability and growth include: - The company is seeing stabilization and marginal growth in some key products like Divatrone from December onwards. - Organic growth is inching up to 8% year-to-date, with overall reported growth influenced significantly by inorganic acquisitions. - The company has a broad portfolio mix with gynae division as core strength contributing about 50% of revenues. - New product launches are planned at 8-10 per year across four divisions to drive growth.

2 more points from Jagsonpal Pharmaceuticals Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹64 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • SMS Pharma. (Q3 FY25)

    Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…

  • Wockhardt (Q3 FY25)

    725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…

  • NGL Fine Chem (Q3 FY25)

    Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…

  • Shree Ganesh Rem (Q3 FY25)

    Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Jagsonpal Pharmaceuticals Ltd Q3 FY25 results?

Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25 on a stable basis. Jagsonpal Pharmaceuticals targets 12% to 14% top-line growth beyond FY25.

What is Jagsonpal Pharmaceuticals Ltd share price analysis?

Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?

No specific mention of current or future capital expenditure (capex) or strategic investments in manufacturing or infrastructure was highlighted.

Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.